74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
CorMedix Inc
Closed
SectorHealthcare
9.03 7.12
Overview
Share price change
24h
Min
8.41
Max
9.12
Income | 16M 13M |
|---|---|
Sales | 20M 31M |
EPS | 0.22 |
Profit margin | 43.141 |
Employees | 64 |
EBITDA | 16M 14M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +91.72% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -123M 531M |
|---|---|
Previous open | 1.91 |
Previous close | 9.03 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
CorMedix Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
CorMedix Inc Forecast
Price Target
By TipRanks
91.72% upside
12 Months Forecast
Average 16.2 USD 91.72%
High 20 USD
Low 12 USD
Based on 6 Wall Street analysts offering 12 month price targets forCorMedix Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About CorMedix Inc
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
